123 related articles for article (PubMed ID: 30098215)
1. A risk-based approach to identifying oligometastatic disease on imaging.
deSouza NM; Tempany CM
Int J Cancer; 2019 Feb; 144(3):422-430. PubMed ID: 30098215
[TBL] [Abstract][Full Text] [Related]
2. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.
deSouza NM; Liu Y; Chiti A; Oprea-Lager D; Gebhart G; Van Beers BE; Herrmann K; Lecouvet FE
Eur J Cancer; 2018 Mar; 91():153-163. PubMed ID: 29331524
[TBL] [Abstract][Full Text] [Related]
3. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
Lievens Y; Guckenberger M; Gomez D; Hoyer M; Iyengar P; Kindts I; Méndez Romero A; Nevens D; Palma D; Park C; Ricardi U; Scorsetti M; Yu J; Woodward WA
Radiother Oncol; 2020 Jul; 148():157-166. PubMed ID: 32388150
[TBL] [Abstract][Full Text] [Related]
4. Modeling growth kinetics and statistical distribution of oligometastases.
Withers HR; Lee SP
Semin Radiat Oncol; 2006 Apr; 16(2):111-9. PubMed ID: 16564446
[TBL] [Abstract][Full Text] [Related]
5. Imaging and its Impact on Defining the Oligometastatic State.
Pirasteh A; Lovrec P; Pedrosa I
Semin Radiat Oncol; 2021 Jul; 31(3):186-199. PubMed ID: 34090645
[TBL] [Abstract][Full Text] [Related]
6. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer.
Conde-Moreno AJ; González-Del-Alba A; López-Campos F; López López C; Requejo OH; de Castro Carpeño J; Chicas-Sett R; de Paz Arias L; Montero-Luis Á; Pérez AR; Font EF; Arija JÁA
Clin Transl Oncol; 2023 Apr; 25(4):897-911. PubMed ID: 36525230
[TBL] [Abstract][Full Text] [Related]
7. Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study.
Ottaiano A; De Luca A; Santorsola M; Scognamiglio G; Di Mauro A; Chiodini P; Lambiase M; Sacco A; Petrillo A; Granata V; Fusco R; Mercadante E; Martucci N; De Luca G; Rocca A; Celentano E; Crispo A; Di Gennaro P; Tatangelo F; Ferrara G; Izzo F; Belli A; Patrone R; Delrio P; Rega D; De Franciscis S; Muto P; Ravo V; Di Franco R; Borzillo V; Santagata S; Rea G; Castaldo D; Pace U; De Feo G; Scala S; Nasti G; Normanno N
BMC Cancer; 2023 Oct; 23(1):1010. PubMed ID: 37858132
[TBL] [Abstract][Full Text] [Related]
8. Imaging of Oligometastatic Disease.
Vietti Violi N; Hajri R; Haefliger L; Nicod-Lalonde M; Villard N; Dromain C
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326586
[TBL] [Abstract][Full Text] [Related]
9. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
Larbi A; Dallaudière B; Pasoglou V; Padhani A; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
Prostate; 2016 Aug; 76(11):1024-33. PubMed ID: 27197649
[TBL] [Abstract][Full Text] [Related]
10. Approach to Oligometastatic Prostate Cancer.
Bernard B; Gershman B; Karnes RJ; Sweeney CJ; Vapiwala N
Am Soc Clin Oncol Educ Book; 2016; 35():119-29. PubMed ID: 27249693
[TBL] [Abstract][Full Text] [Related]
11. Imaging oligometastatic cancer before local treatment.
Franklin JM; Sharma RA; Harris AL; Gleeson FV
Lancet Oncol; 2016 Sep; 17(9):e406-14. PubMed ID: 27599145
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of Whole-Body DWI for Metastases Screening in a Diverse Group of Malignancies: Comparison With Conventional Cross-Sectional Imaging and Nuclear Scintigraphy.
Paruthikunnan SM; Kadavigere R; Karegowda LH
AJR Am J Roentgenol; 2017 Sep; 209(3):477-490. PubMed ID: 28678578
[TBL] [Abstract][Full Text] [Related]
13. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group.
Falk AT; Moureau-Zabotto L; Ouali M; Penel N; Italiano A; Bay JO; Olivier T; Sunyach MP; Boudou-Roquette P; Salas S; Le Maignan C; Ducassou A; Isambert N; Kalbacher E; Pan C; Saada E; Bertucci F; Thyss A; Thariat J;
Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):48-55. PubMed ID: 25300878
[TBL] [Abstract][Full Text] [Related]
14. PET/CT: will it change the way that we use CT in cancer imaging?
Hicks RJ; Ware RE; Lau EW
Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Treatment of Oligometastatic Disease: What the Radiologist Needs to Know to Guide Patient Management.
Rowe SP; Hawasli H; Fishman EK; Johnson PT
Acad Radiol; 2016 Mar; 23(3):326-8. PubMed ID: 26781202
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease.
Bhattacharya IS; Woolf DK; Hughes RJ; Shah N; Harrison M; Ostler PJ; Hoskin PJ
Br J Radiol; 2015 Apr; 88(1048):20140712. PubMed ID: 25679321
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of whole-body diffusion-weighted magnetic resonance imaging with 3.0 T in detection of primary and metastatic neoplasms.
Akay S; Kocaoglu M; Emer O; Battal B; Arslan N
J Med Imaging Radiat Oncol; 2013 Jun; 57(3):274-82. PubMed ID: 23721135
[TBL] [Abstract][Full Text] [Related]
18. Whole-body MRI for the staging and follow-up of patients with metastasis.
Schmidt GP; Reiser MF; Baur-Melnyk A
Eur J Radiol; 2009 Jun; 70(3):393-400. PubMed ID: 19457631
[TBL] [Abstract][Full Text] [Related]
19. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.
Joice GA; Rowe SP; Pienta KJ; Gorin MA
Curr Opin Urol; 2017 Nov; 27(6):533-541. PubMed ID: 28863016
[TBL] [Abstract][Full Text] [Related]
20. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
